3 results
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
Three months ended March 31, | ||||||||||||||||
2024 | 2023 | Change | ||||||||||||||
($'000) | ($'000) | ($'000) | % | |||||||||||||
Setrusumab (BPS-804/UX143) | 909 | 652 | 257 | 39 | % | |||||||||||
Alvelestat (MPH-966) | 2,613 | 2,340 | 273 | 12 | % | |||||||||||
Etigilimab (MPH-313) | 350 | 2,153 | (1,803) | (84 | %) | |||||||||||
Leflutrozole (BGS-649) | 36 | 60 | (24) | (40 | %) | |||||||||||
Acumapimod (BCT-197) | 8 | 4 | 4 | 100 | % | |||||||||||
Other | 78 | 98 | (20) | (20 | %) | |||||||||||
Total R&D expenses | 3,994 | 5,307 | (1,313) | (25 | %) |
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
Year ended December 31, | |||||||
2023 | 2022 | ||||||
(%) | (%) | ||||||
Income tax using U.K. statutory rate | 23.5 | 19.0 | |||||
Effect of rate change on opening tax balances | — | — | |||||
Effect of rate change on current and deferred taxes | — | — | |||||
Permanent differences | (5.4) | (5.3) | |||||
U.K. R&D tax credits | (1.9) | (1.4) | |||||
Changes in deferred tax valuation allowance | (15.7) | (13.9) | |||||
Foreign rate differential | (0.7) | 0.9 | |||||
Adjustments in respect of prior years | 1.9 | 1.8 | |||||
Other | 0.2 | 1.2 | |||||
Effective tax rate for loss from continuing operations | 1.77 | 1.8 |
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
Year ended December 31, | ||||||||||||||||
2023 | 2022 | Change | ||||||||||||||
($'000) | ($'000) | ($'000) | % | |||||||||||||
Setrusumab (BPS-804/UX143) | 3,157 | 2,443 | 714 | 29 | % | |||||||||||
Alvelestat (MPH-966) | 6,730 | 6,899 | (169) | (2 | %) | |||||||||||
Etigilimab (MPH-313) | 7,263 | 19,620 | (12,357) | (63 | %) | |||||||||||
Leflutrozole (BGS-649) | 114 | 71 | 43 | 61 | % | |||||||||||
Acumapimod (BCT-197) | 28 | 64 | (36) | (56 | %) | |||||||||||
Other | 126 | 368 | (242) | (66 | %) | |||||||||||
Total R&D expenses | 17,418 | 29,465 | (12,047) | (41 | %) |
- Prev
- 1
- Next